DOCSLIB.ORG

Current Molecular and Clinical Insights Into Uveal Melanoma (Review)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Current Molecular and Clinical Insights Into Uveal Melanoma (Review) INTERNATIONAL JOURNAL OF ONCOLOGY 58: 10, 2021 Current molecular and clinical insights into uveal melanoma (Review) MATTEO FALLICO1*, GIUSEPPINA RACITI2*, ANTONIO LONGO1, MICHELE REIBALDI3, VINCENZA BONFIGLIO4, ANDREA RUSSO1, ROSARIO CALTABIANO5, GIUSEPPE GATTUSO6, LUCA FALZONE7 and TERESIO AVITABILE1 1Department of Ophthalmology, University of Catania, I‑95123 Catania; 2Department of Drug Sciences, Section of Biochemistry, University of Catania, I‑95125 Catania; 3Department of Surgical Sciences, Eye Clinic Section, University of Turin, I‑10122 Turin; 4Department of Experimental Biomedicine and Clinical Neuroscience, Ophthalmology Section, University of Palermo, I‑90127 Palermo; 5Department ‘G.F. Ingrassia’, Section of Anatomic Pathology, and 6Department of Biomedical and Biotechnological Sciences, University of Catania, I‑95123 Catania; 7Epidemiology Unit, IRCCS Istituto Nazionale Tumori ‘Fondazione G. Pascale’, I‑80131 Naples, Italy Received October 27, 2020; Accepted November 30, 2020 DOI: 10.3892/ijo.2021.5190 Abstract. Uveal melanoma (UM) represents the most aggressiveness of the condition. Novel molecular studies prominent primary eye cancer in adults. With an incidence have allowed for a better understanding of the genetic of approximately 5 cases per million individuals annually and epigenetic mechanisms involved in UM biological in the United States, UM could be considered a relatively activity, which differs compared to skin melanomas. The rare cancer. The 90‑95% of UM cases arise from the most commonly mutated genes are GNAQ, GNA11 and choroid. Diagnosis is based mainly on a clinical examina‑ BAP1. Research in this field could help to identify effec‑ tion and ancillary tests, with ocular ultrasonography being tive diagnostic and prognostic biomarkers, as well as novel of greatest value. Differential diagnosis can prove chal‑ therapeutic targets. lenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be Contents performed with a prognostic purpose, often in combination with radiotherapy. Gene expression profiling has allowed for 1. Introduction the grading of UMs into two classes, which feature different 2. Epidemiology metastatic risks. Patients with UM require a specialized 3. Risk factors multidisciplinary management. Primary tumor treatment 4. Clinical characteristics can be either enucleation or globe preserving. Usually, 5. Diagnosis enucleation is reserved for larger tumors, while radiotherapy 6. Staging is preferred for small/medium melanomas. The prognosis is 7. Prognosis unfavorable due to the high mortality rate and high tendency 8. Primary tumor treatment to metastasize. Following the development of metastatic 9. Surveillance and metastatic disease treatment disease, the mortality rate increases to 80% within one year, 10. Genetic and epigenetic features in uveal melanoma due to both the absence of an effective treatment and the 11. Conclusions 1. Introduction Correspondence to: Dr Luca Falzone, Epidemiology Unit, IRCCS Uveal melanoma (UM) represents the most prominent primary Istituto Nazionale Tumori ‘Fondazione G. Pascale’, Via Mariano eye cancer in adults. Although it could be considered a rela‑ Semmola 53, I‑80131 Naples, Italy E‑mail: [email protected] tively rare tumor, UM remains a disease of primary interest due to its high mortality rate. *Contributed equally Notable efforts have been made to improve the manage‑ ment of this malignancy. The introduction of globe‑sparing Key words: uveal melanoma, staging, treatment, diagnosis, treatments was the most significant breakthrough of the last prognosis, biomarkers, epigenetics century in this field. However, the overall survival of affected patients has remained unaltered, and there is still no effective treatment for metastatic disease. 2 FALLICO et al: INSIGHTS INTO UVEAL MELANOMA Recently, increasing attention has focused on the 3. Risk factors molecular mechanisms involved in UM carcinogenesis and progression, which could allow for the identification of valu‑ Several risk factors have been associated with the develop‑ able diagnostic and prognostic biomarkers, as well as novel ment of UM. Host susceptibility variables, such as fair skin therapeutic targets. color, inability to tan and light eye color have been signifi‑ Herein, the available evidence on epidemiological, clinical cantly associated with UM, with a risk ratio of 1.80, 1.64 and and molecular aspects of UM is discussed and reviewed, with 1.75, respectively (19). This association is likely to be related an aim of providing an updated and comprehensive tool, which to the poor amount of melanin in the skin and eyes. It has may be useful for both clinicians and researchers. been assumed that a poor amount of melanin is present in the choroid and retinal pigment epithelium, leading to an 2. Epidemiology increased susceptibility to ultraviolet light and a higher risk of developing UM (19). Oculodermal melanocytosis, also known UM represents 3‑5% of all melanomas (1,2). The largest as Nevus of Ota, represents a relevant risk factor for developing proportion of cases of UM, approximately 85‑90%, arises UM (20,21). This condition is characterized by an abnormal from the choroid, while the 5‑8% arises from the ciliary congenital hyper‑pigmentation within the V1/V2 trigeminal body and the 3‑5% from the iris (2,3). The incidence nerve area, and can involve periocular skin, orbit, uvea, sclera of UM in the United States, between 1973 and 2008, and conjunctiva, as well as the palate, meninges and tympanic amounted to 5.1 cases per million annually (4). In Europe, membrane (20,21). Usually this condition is unilateral and, a cancer registry‑based study demonstrated a north‑to‑south is mostly confined to the eye. Oculodermal melanocytosis is decreasing gradient in the incidence of UM, with an inci‑ 35‑fold more common in patients with UM compared to the dence of >8 cases per million in Norway and Denmark healthy population: The incidence rate among the Caucasian compared with approximately 2 cases per million in Spain population is 0.04 vs. 1.4% to 3% in patients with UM (20,21). and Southern Italy (5). Likewise, in Africa and Asia, the A Caucasian patient affected by oculodermal melanocytosis incidence is low, amounting to 0.2‑0.3 cases per million presents a lifetime risk for developing UM equal to 1:400 (22). per year (6). This latitude‑related decreasing trend in the The presence of atypical cutaneous nevi and intraocular incidence of UM has been associated with the protective nevi has been also associated with the development of UM. role of ocular pigmentation, which is higher in southern In particular, the risk of developing UM is 4‑10‑fold higher countries compared to northern ones (5). Similarly, dark in patients affected by atypical cutaneous nevi than in the skin pigmentation may play a role in protecting populations healthy population (23,24). Intraocular nevi, such as iris nevi of African origin: The ratio of UM among populations of and choroidal nevi, are considered risk factors for UM. Iris African origin vs. Caucasian populations ranges from 1:15 nevi have been reported to have a potential risk of malignant to 1:50 (7‑9). A population‑based study investigated the rela‑ transformation, although the rate of this transformation has not tive risk of UM in several racial cohorts, revealing a 5‑fold been clearly established, ranging from 2‑5% (25,26). Predictive higher risk among Hispanic populations and 19‑fold higher factors for an iris nevus to transform into an iris melanoma risk among non‑Hispanic Caucasian populations compared have been summarized in the ABCDEF acronym: A stands populations of African origin (9). for young age; B stands for blood; C stands for clock‑hour UM is typically an adult malignancy, affecting older age (inferior location); D stands for diffuse flat shape; E stands for groups (10). The median age at diagnosis has been reported ectropion uveae; F stands for feathery margins (26). Choroidal to be approximately 62 years (2), with an incidence rate that nevus is a common finding in the healthy population, with an tends to increase progressively up to 70 years of age, and incidence rate of approximately 5% in the United States (27). then levels off after 75 years of age (4,5,10,11). The mean age Based on the concept that all melanomas originate from a at diagnosis for UM seems to decrease from 59‑62 years of nevus, the rate of transformation of a choroidal nevus into age in Caucasians, (4,12) to 55 years in Japanese, 51 years in melanoma has been reported as 1:8845, increasing to 1:3664 in Taiwanese and 45 years in Chinese populations (13‑15). UM the older aged cohort (80‑84 years old) (28). Predictive factors is uncommon in children and extremely rare in newborns; for a choroidal melanoma to become malignant are a thickness congenital melanoma is also rare (11,16,17). Shields et al of >2 mm, the presence of subretinal fluid, presence of orange investigated the incidence rate of UM in children and teenagers, pigment, proximity to optic disc, the absence of drusen or halo and demonstrated that 50% of cases were >15 years of age, 35% and ultrasonographic hollowness (29,30). were between 10 and 15 years, 11% between 5 and 10 years, A further relevant risk factor for the development of UM is and only 3% of cases were between 0 and 5 years of age at the the mutation of the onco‑suppressor gene, BRCA1 associated time of diagnosis (17). protein 1 (BAP1) (10,31). BAP1 is located on chromosome 3. The incidence of UM appears to be related to sex as The mutation of this gene has been associated with a hereditary well (2,10). Population‑based studies have demonstrated a cancer syndrome. Tumors, such as malignant mesothelioma, higher age‑adjusted incidence in the male sex compared basal cell carcinoma, cutaneous melanomas, UMs and renal to females, with a 20‑30% greater rate in males (1,4).
Load more

Recommended publications
  • Optic Nerve Invasion of Uveal Melanoma: Clinical Characteristics and Metastatic Pattern
    Optic Nerve Invasion of Uveal Melanoma: Clinical Characteristics and Metastatic Pattern Jens Lindegaard,1,2 Peter Isager,3,4 Jan Ulrik Prause,1,2 and Steffen Heegaard1 PURPOSE. To determine the frequency of optic nerve invasion in present independently of decreased visual acuity and tumor uveal melanoma, to identify clinical factors associated with location. (Invest Ophthalmol Vis Sci. 2006;47:3268–3275) optic nerve invasion, and to analyze the metastatic pattern and DOI:10.1167/iovs.05-1435 the association with survival. METHODS. All iris, ciliary body, and choroidal melanomas (N ϭ veal melanoma is the most frequent primary intraocular 2758) examined between 1942 and 2001 at the Eye Pathology Umalignant tumor in adults; in Scandinavia, the incidence 1–4 Institute, University of Copenhagen, Denmark, and the Insti- rate is 5.3 to 8.7 per million person-years. The tumor has a tute of Pathology, Aarhus University Hospital, Aarhus, Den- great propensity to metastasize and to affect the liver in par- 3,5,6 mark, were reviewed. Cases with optic nerve invasion were ticular. Local spread occurs through the overlying Bruch identified and subdivided into prelaminar or laminar invasion membrane, giving access to the subretinal space, or toward the and postlaminar invasion. Clinical characteristics were com- orbit (through the sclera, most often along ciliary vessels and pared with those from 85 cases randomly drawn from all ciliary nerves). Uveal melanoma infiltrates the optic nerve in only body and choroidal melanomas without optic nerve invasion 0.6% to 5% of patients and has been associated with high intraocular pressure, non–spindle cell type, juxtapapillary lo- from the same period.
    [Show full text]
  • Retinoblastoma Major Review with Updates on Middle East Management Protocols
    Saudi Journal of Ophthalmology (2012) 26, 163–175 Ophthalmic Pathology Update Retinoblastoma major review with updates on Middle East management protocols ⇑ Ihab Saad Othman, MD, FRCS Abstract Many advances in the field of management of retinoblastoma emerged in the past few years. Patterns of presentation of retino- blastoma in the Middle East region differ from Western community. The use of enucleation as a radical method of eradicating advanced disease is not easily accepted by patient’s family. We still do see stage E, failed or resistant retinoblastoma and advanced extraocular disease ensues as a result of delayed enucleation decision. In this review, we discuss updates in management of retinoblastoma with its implication on patients in our part of the world. Identifying clinical and high risk characteristics is impor- tant prognostically and are discussed for further management of retinoblastoma cases. Keywords: Retinoblastoma, Staging, Classification, Histopathology, Middle East Ó 2012 Saudi Ophthalmological Society, King Saud University. All rights reserved. http://dx.doi.org/10.1016/j.sjopt.2012.03.002 Introduction cases is 100–120 cases/year.3 In a recent report from Jordan, the mean age-adjusted incidence of retinoblastoma was 9.32 Retinoblastoma is the commonest primary ocular malig- cases per million children per year for children aged 0– nancy of childhood originating from primitive retinoblasts 5 years.4 Retinoblastoma constituted 4.8% of childhood can- with tendency towards cone differentiation. Retinoblasts cer treated over 10 years at the National Cancer Institute in arise from the inner neuroepithelial layers of the embryonic Sudan and presented in an advanced stage in 16 out of 25 re- optic cup.1 The incidence of retinoblastoma ranges from 1/ ported cases.5 15,000 to 1/20,000 live births with an annual incidence in chil- dren younger than 5 years of 10.9/million.
    [Show full text]
  • Glaucoma Related to Ocular and Orbital Tumors Sonal P
    Chapter Glaucoma Related to Ocular and Orbital Tumors Sonal P. Yadav Abstract Secondary glaucoma due to ocular and orbital tumors can be a diagnostic challenge. It is an essential differential to consider in eyes with a known tumor as well as with unilateral, atypical, asymmetrical, or refractory glaucoma. Various intraocular neoplasms including iris and ciliary body tumors (melanoma, metasta- sis, lymphoma), choroidal tumors (melanoma, metastasis), vitreo-retinal tumors (retinoblastoma, medulloepithelioma, vitreoretinal lymphoma) and orbital tumors (extra-scleral extension of choroidal melanoma or retinoblastoma, primary orbital tumors) etc. can lead to raised intraocular pressure. The mechanisms for glaucoma include direct (tumor invasion or infiltration related outflow obstruction, tra- becular meshwork seeding) or indirect (angle closure from neovascularization or anterior displacement or compression of iris) or elevated episcleral venous pressure secondary to orbital tumors. These forms of glaucoma need unique diagnostic techniques and customized treatment considerations as they often pose therapeutic dilemmas. This chapter will review and discuss the mechanisms, clinical presenta- tions and management of glaucoma related to ocular and orbital tumors. Keywords: ocular tumors, secondary glaucoma, orbital tumors, angle infiltration, neovascular glaucoma, neoplastic glaucoma 1. Introduction With the advent of constantly evolving and advancing ophthalmic imaging tech- niques as well as surgical modalities in the field of ophthalmic diseases, diagnostic accuracy, and treatment outcomes of ocular as well as orbital tumors have improved remarkably over the past few years. Raised intraocular pressure (IOP) is known to be one of the presenting features or associated finding for numerous ocular as well as orbital tumors. Ocular and orbital tumors can cause secondary glaucoma due to various mechanisms.
    [Show full text]
  • Small Choroidal Melanoma with All Eight Risk Factors for Growth
    RETINAL ONCOLOGY CASE REPORTS IN OCULAR ONCOLOGY SECTION EDITOR: CAROL L. SHIELDS, MD Small Choroidal Melanoma With All Eight Risk Factors for Growth BY FELINA V. ZOLOTAREV, BA; KIRAN TURAKA, MD; AND CAROL L. SHIELDS, MD veal melanoma prognosis is A B C dependent on several factors including tumor size, location, U configuration, extraocular extension, cell type, and cytogenetic abnormalities. In general, the smaller the tumor, the better the prognosis.1 In a recent publication on 8,033 eyes with DE uveal melanoma, it was documented that increasing thickness of uveal melanoma was associated with greater risk for metastasis and ultimate death.1 Patients with uveal melanoma measuring 2.5 mm Figure 1. Features of small choroidal melanoma. A pigmented choroidal tumor thickness showed metastasis in 12% at 10 superior to the macula displays orange pigment, seen on autofluorescence (A, years as compared with 26% for those at B), hollowness on ultrasonography (C), and subretinal fluid, depicted on opti- 4.5 mm thickness.1 Hence, early detection cal coherence tomography (D, E). Note the lack of drusen or halo.These fea- of uveal melanoma is important. tures are most consistent with melanoma. The dilemma of early recognition cen- ters on the difficulty in differentiating a benign melanoma display two or three of these factors.2 In this choroidal nevus from a small malignant melanoma. Risk case presentation, we describe a small melanoma with factors for identification of small melanoma, when it all eight risk factors and discuss the importance of early might resemble choroidal nevus, have been identified detection of uveal melanoma.
    [Show full text]
  • Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation
    cancers Article Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation Thupten Tsering 1, Alexander Laskaris 1, Mohamed Abdouh 1 , Prisca Bustamante 1 , Sabrina Parent 1 , Eva Jin 1, Sarah Tadhg Ferrier 1, Goffredo Arena 1,2,3 and Julia V. Burnier 1,4,* 1 Cancer Research Program, Research Institute of the McGill University Health Centre, 1001 Decarie Blvd, Montreal, QC H4A 3J1, Canada; [email protected] (T.T.); [email protected] (A.L.); [email protected] (M.A.); [email protected] (P.B.); [email protected] (S.P.); [email protected] (E.J.); [email protected] (S.T.F.); goff[email protected] (G.A.) 2 Ospedale Giuseppe Giglio Fondazione San Raffaele Cefalu Sicily, 90015 Cefalu, Italy 3 Mediterranean Institute of Oncology, 95029 Viagrande, Italy 4 Experimental Pathology Unit, Department of Pathology, McGill University, QC H3A 2B4, Canada * Correspondence: [email protected]; Tel.: +1-514-934-1934 (ext. 76307) Received: 13 September 2020; Accepted: 7 October 2020; Published: 11 October 2020 Simple Summary: Uveal melanoma is a rare but deadly cancer that shows remarkable metastatic tropism to the liver. Extracellular vesicles (EVs) are nanometer-sized, lipid bilayer-membraned particles that are released from cells. In our study we used EVs derived from primary normal choroidal melanocytes and matched primary and metastatic uveal melanoma cell lines from a patient. Analysis of these EVs revealed important protein signatures that may be involved in tumorigenesis and metastatic dissemination. We have established a model to study EV functions and phenotypes which can be used in EV-based liquid biopsy.
    [Show full text]
  • Melanomas Are Comprised of Multiple Biologically Distinct Categories
    Melanomas are comprised of multiple biologically distinct categories, which differ in cell of origin, age of onset, clinical and histologic presentation, pattern of metastasis, ethnic distribution, causative role of UV radiation, predisposing germ line alterations, mutational processes, and patterns of somatic mutations. Neoplasms are initiated by gain of function mutations in one of several primary oncogenes, typically leading to benign melanocytic nevi with characteristic histologic features. The progression of nevi is restrained by multiple tumor suppressive mechanisms. Secondary genetic alterations override these barriers and promote intermediate or overtly malignant tumors along distinct progression trajectories. The current knowledge about pathogenesis, clinical, histological and genetic features of primary melanocytic neoplasms is reviewed and integrated into a taxonomic framework. THE MOLECULAR PATHOLOGY OF MELANOMA: AN INTEGRATED TAXONOMY OF MELANOCYTIC NEOPLASIA Boris C. Bastian Corresponding Author: Boris C. Bastian, M.D. Ph.D. Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology Departments of Dermatology and Pathology University of California, San Francisco UCSF Cardiovascular Research Institute 555 Mission Bay Blvd South Box 3118, Room 252K San Francisco, CA 94158-9001 [email protected] Key words: Genetics Pathogenesis Classification Mutation Nevi Table of Contents Molecular pathogenesis of melanocytic neoplasia .................................................... 1 Classification of melanocytic neoplasms
    [Show full text]
  • ICO Residency Curriculum 2Nd Edition and Updated Community Eye Health Section
    ICO Residency Curriculum 2nd Edition and Updated Community Eye Health Section The International Council of Ophthalmology (ICO) Residency Curriculum offers an international consensus on what residents in ophthalmology should be taught. While the ICO curriculum provides a standardized content outline for ophthalmic training, it has been designed to be revised and modified, with the precise local detail for implementation left to the region’s educators. Download the Curriculum from the ICO website: icoph.org/curricula.html. www.icoph.org Copyright © International Council of Ophthalmology 2016. Adapt and translate this document for your noncommercial needs, but please include ICO credit. All rights reserved. First edition 201 6 . First edition 2006, second edition 2012, Community Eye Health Section updated 2016. International Council of Ophthalmology Residency Curriculum Introduction “Teaching the Teachers” The International Council of Ophthalmology (ICO) is committed to leading efforts to improve ophthalmic education to meet the growing need for eye care worldwide. To enhance educational programs and ensure best practices are available, the ICO focuses on "Teaching the Teachers," and offers curricula, conferences, courses, and resources to those involved in ophthalmic education. By providing ophthalmic educators with the tools to become better teachers, we will have better-trained ophthalmologists and professionals throughout the world, with the ultimate result being better patient care. Launched in 2012, the ICO’s Center for Ophthalmic Educators, educators.icoph.org, offers a broad array of educational tools, resources, and guidelines for teachers of residents, medical students, subspecialty fellows, practicing ophthalmologists, and allied eye care personnel. The Center enables resources to be sorted by intended audience and guides ophthalmology teachers in the construction of web-based courses, development and use of assessment tools, and applying evidence-based strategies for enhancing adult learning.
    [Show full text]
  • Posterior Uveal (Ciliary Body and Choroidal) Melanoma Leslie T
    Posterior Uveal (Ciliary Body and Choroidal) Melanoma Leslie T. L. Pham, MD, Jordan M. Graff, MD, and H. Culver Boldt, MD July 27, 2010 Chief Complaint: 31-year-old man with "floaters and blurry vision" in the right eye (OD). History of Present Illness: In August 2007, a healthy 31-year-old truck driver from Nebraska started noticing floaters in his right eye. The floaters gradually worsened and clouded his central vision. His family doctor tried changing his blood pressure medications, but this did not help. He later saw an ophthalmologist in his home state who told him there was a "mass" in his right eye. He was referred to the University of Iowa Department of Ophthalmology and Visual Sciences. Past Ocular History: The patient has had no prior eye surgery or trauma. Past Medical History: The patient reports prior excision of a benign skin nevus. He also has hypertension. Medications: Metoprolol and triamterene/hydrochlorothiazide Family History: The patient’s mother has a history of neurofibromatosis. His father had an enucleation for an "eye cancer" and subsequently died due to metastatic spread of the cancer. His grandmother had skin melanoma. Social History: The patient lives in Nebraska with his wife and child. He has never smoked and only drinks on "special occasions". Review of Systems: Negative, except as noted above. Ocular Examination: General: Well-developed, well-nourished Caucasian man in a pleasant mood Skin: Several scattered macules and papules on the trunk and all four extremities Distance visual acuity (without correction): o 20/60-2 OD o 20/20 OS Near acuity (without correction) o 20/30 OD o 20/20 OS Ocular motility: Full OU.
    [Show full text]
  • Families with BAP1-Tumor Predisposition Syndrome in the Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines
    cancers Article Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines Cindy Chau 1 , Remco van Doorn 2, Natasha M. van Poppelen 3,4, Nienke van der Stoep 5, Arjen R. Mensenkamp 6 , Rolf H. Sijmons 7, Barbara W. van Paassen 3, Ans M. W. van den Ouweland 3, Nicole C. Naus 4, Annemieke H. van der Hout 7, Thomas P. Potjer 5, Fonnet E. Bleeker 8, Marijke R. Wevers 6, Liselotte P. van Hest 9, Marjolijn C. J. Jongmans 6,10, Marina Marinkovic 1, Jaco C. Bleeker 1, Martine J. Jager 1 , Gregorius P. M. Luyten 1 and Maartje Nielsen 5,* 1 Department of Ophthalmology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 2 Department of Dermatology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 3 Department of Clinical Genetics, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 4 Department of Ophthalmology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands 5 Department of Clinical Genetics, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands 6 Department of Clinical Genetics, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands 7 Department of Genetics, University Medical Center Groningen, 9713 GZ Groningen, The Netherlands 8 Department of Clinical Genetics, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands 9 Department of Clinical Genetics, Amsterdam University Medical Centers, 1081 HV Amsterdam, The Netherlands 10 Department of Clinical Genetics, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands * Correspondence: [email protected] Received: 30 June 2019; Accepted: 1 August 2019; Published: 4 August 2019 Abstract: Germline pathogenic variants in the BRCA1-associated protein-1 (BAP1) gene cause the BAP1-tumor predisposition syndrome (BAP1-TPDS, OMIM 614327).
    [Show full text]
  • Download Report Appendixes [PDF · 224
    Appendices Appendix A. Selected Internet Links Appendix Table A1. Internet links for radiotherapy organizations Organization URL address Deutsche Gesellschaft fur http://www.degro.org/jsp_public/cms/index.jsp Radiooncologie European Society for Therapeutic http://www.estroweb.org/estro/index.cfm Radiology and Oncology American Society for Therapeutic http://www.astro.org/ Radiology and Oncology National Association for Proton http://www.proton-therapy.org/ Therapy Particle Therapy Cooperative http://ptcog.web.psi.ch/ Group (Accessed June 16, 2008) Appendix Table A2. Internet links for particle beam instrumentation companies Company URL address Ion Beam Applications (IBA) http://www.iba-worldwide.com/ Solutions Still River Systems Inc http://www.stillriversystems.com/ Optivus Proton Therapy http://www.optivus.com/ Siemens http://www.medical.siemens.com/ Hitachi: Proton beam Therapy http://www.pi.hitachi.co.jp/rd-eng/product/industrial-sys/accelerator- sys/proton-therapy-sys/proton-beam-therapy/index.html ACCEL Instruments http://www.proton-therapy.com/ (Accessed June 16, 2008) Appendix Table A3. Internet links for particle beam treatment centers in the USA Center/Institute URL address Francis H. Burr Proton Therapy http://www.massgeneral.org/cancer/about/providers/radiation/proton/i Center (NPTC) ndex.asp Loma Linda University Proton http://www.llu.edu/proton/index.html Therapy Center University of California, Crocker http://media.cnl.ucdavis.edu/crocker/website/default.php Nuclear Lab Midwest Proton Radiotherapy http://www.mpri.org/ Institute, Bloomington M.D. Anderson Proton Therapy http://www.mdanderson.org/care_centers/radiationonco/ptc/ Center, Houston University of Florida Proton http://www.floridaproton.org/ Therapy Institute, Jacksonville (Accessed June 16, 2008) A-1 Appendix B.
    [Show full text]
  • Genetic Testing for Uveal Melanoma, MPM
    Medical Policy Subject: Genetic Testing for Uveal Melanoma Medical Policy #: 7.9 Original Effective Date: 11/20/2019 Status: Review Last Review Date: 01-27-2021 Disclaimer Refer to the member’s specific benefit plan and Schedule of Benefits to determine coverage. This may not be a benefit on all plans or the plan may have broader or more limited benefits than those listed in this Medical Policy. Description Uveal melanoma is a rare cancer, and most common intra-ocular cancer in adults. DecisionDx-UM is an RNA gene expression classifier that is based on the expression levels of 15 mRNA transcripts (3 control and 12 discriminating genes). DecisionDx-UM is performed on tissue from a fresh-frozen fine needle aspirate biopsy (FNAB), formalin-fixed paraffin embedded (FFPE) sections from an enucleated tumor, or, in rare cases, fresh-frozen resection material. DecisionDX-UM results are reported as a 5-year risk classification for metastasis: low-risk (Class 1A), intermediate risk (Class 1B), or high risk (Class 2). Coverage Determination Prior Authorization is required. Logon to Pres Online to submit a request: https://ds.phs.org/preslogin/index.jsp Decision Dx-UM (Uveal Melanoma) test is covered for Medicare, Medicaid (Centennial) and Commercial members. Presbyterian Health Plan considers DecisionDX-UM (uveal melanoma) medically necessary and uses two-mandated coverage statements to address this benefit. PHP follows CMS MoIDX: Decision Dx-UM (Uveal Melanoma) (L37210) and LCD Biomarkers for Oncology (L35396) for Prognostic of Uveal Melanoma (GNAQ and GNA11). DecisionDX-UM assay is intended for determination of metastatic risk, and to guide surveillance and referral to medical oncology in patients who have a confirmed diagnosis of uveal melanoma (UM) and no evidence of metastatic disease.
    [Show full text]
  • Optic Nerve: Developmental Anomalies and Common Tumors
    DOI: 10.5772/intechopen.80326 ProvisionalChapter chapter 3 Optic Nerve: Developmental Anomalies and Common Tumors HindHind Alkatan, Alkatan, Daniah AlshowaeirDaniah Alshowaeir and TariqTariq Alzahem Alzahem Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.80326 Abstract The optic nerve, also known as the second cranial nerve, is composed of axons that trans- mit visual information from the neurosensory retina to the visual cortex. There are mul- tiple pathologies that can affect the human optic nerve. Congenital anomalies of the optic nerve include myelinated nerve fibers, morning glory syndrome, optic nerve choristoma, optic nerve coloboma, optic nerve hypoplasia and aplasia, and others. Tumors that can affect the optic nerve (ON) may occur primarily from within the nerve itself, from the sur- rounding optic nerve sheath (ONS), or secondarily spreading to the nerve from a distant site. They include optic pathway glioma, medulloepithelioma, oligodendroglioma, optic nerve sheath meningioma, and others. Here in this chapter, we will review the optic nerve anatomy, embryology, and physiology in addition to assessment of optic nerve function. Moreover, the clinical features, imaging findings, pathology, and treatment options of the most common and some rare congenital anomalies and primary tumors of the ON and sheath will be reviewed. Keywords: myelinated nerve fibers, morning glory syndrome, optic nerve choristoma, optic nerve coloboma, optic nerve hypoplasia, aplasia, optic nerve tumor, glioma, meningioma, ganglioglioma, medulloepithelioma, hemangioblastoma, oligodendroglioma 1. Introduction Visual perception occurs when light stimulus in the surrounding environment converts to nerve impulses at the level of photoreceptors, which then reach the brain to be processed.
    [Show full text]